Roger Longman's guest appearances

Roger Longman

OIS Podcast

Talk at the Top | BioPharma | Talent | Healthcare | Life Sciences | Leadership

Biotalk

Jay Cormier

Brent Saunders

Daniel Chao

David Muller

Andrew Chang

David Tanzer

Ken Mills

Bill Link

Patrick Mooney

Diana Driscoll

Brent Jones

Ponders IPO

Jay Duker

Steve Charles

Join BIO Board

OwlTail

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making. Highlights of the conversation include:  Major shifts in the pharmaceutical industry in recent decades Why pharmaceutical pricing and reimbursement became such a ‘hot button’ topic Trends towards value-based pricing and ‘pay for performance’ approached Recent high profile product launches and pricing decisions Implications of pricing / reimbursement environment on life science deal making and business development 

In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making. Highlights of the conversation include: <ul> <li>Major shifts in the pharmaceutical industry in recent decades</li> <li>Why pharmaceutical pricing and reimbursement became such a ‘hot button’ topic</li> <li>Trends towards value-based pricing and ‘pay for performance’ approached</li> <li>Recent high profile product launches and pricing decisions</li> <li>Implications of pricing / reimbursement environment on life science deal making and business development</li> </ul>

Episode 3: Roger Longman, Real Endpoints

Don’t miss my discussion with Roger Longman, CEO of Real Endpoints, as we dive into the hotly contested issue of drug pricing in America. You’ll understand why Fortune Magazine named Roger to the drug pricing “Dream Team” (March, 2016 issue) as someone who could help fix the problem.    You’ll hear Roger’s insights on the following:    Is it fair to point the finger at the drug makers for the unsustainable pricing of prescription drugs today?     What should pharma and biotech companies being doing differently given the current climate?       What can payers and PBMs be doing differently?     What kind of talent is needed in the pharma and payer sectors?      Why the big focus on orphan and specialty drugs. Don’t we need more focus on common chronic illnesses, such as diabetes?      What is the future of outcomes-based reimbursement?     Learn how Real Endpoints helps payers and pharma companies to be more savvy in dealing with today’s unpredictable environment.  

Don’t miss my discussion with Roger Longman, CEO of Real Endpoints, as we dive into the hotly contested issue of drug pricing in America. You’ll understand why Fortune Magazine named Roger to the drug pricing “Dream Team” (March, 2016 issue) as someone who could help fix the problem.  You’ll hear Roger’s insights on the following: <ul> <li>Is it fair to point the finger at the drug makers for the unsustainable pricing of prescription drugs today?</li> </ul> <ul> <li>What should pharma and biotech companies being doing differently given the current climate?  </li> </ul> <ul> <li>What can payers and PBMs be doing differently?</li> </ul> <ul> <li>What kind of talent is needed in the pharma and payer sectors? </li> </ul> <ul> <li>Why the big focus on orphan and specialty drugs. Don’t we need more focus on common chronic illnesses, such as diabetes? </li> </ul> <ul> <li>What is the future of outcomes-based reimbursement?</li> </ul> <ul> <li>Learn how Real Endpoints helps payers and pharma companies to be more savvy in dealing with today’s unpredictable environment. </li> </ul>

05: Roger Longman on the Drug Pricing War 